Review of Diabetic Studies最新文献

OBJECTIVE: To evaluate vitamin D ((25OH)D levels) deficiency as a possible cause in the development of DT1 in children and adolescents aged 0-15. METHODS: We searched PubMed/ Medline, EBSCO, and Cochrane Library to identify potentially eligible articles that examine whether low serum 25(OH)D levels are associated with subsequent development of DT1. All type of research designs, including randomized and non-randomized controlled trials, prospective and retrospective cohort studies, case- control and cross-sectional studies with subjects aged ≤15 years old were consider for inclusion. RESULTS: Seven original studies met the entry criteria. Most of these studies found up to 50% lower levels of vitamin D in children with DT1 compared to control group and a significant positive association between vitamin D levels and of the risk of developing DT1. Results of quality assessment demonstrated moderate to high quality of all the studies included. CONCLUSIONS: Vitamin D deficiency may be a possible cause in the development of DT1 in the early years of life and particularly in children with genetic predisposition, whilst the deficiency of vitamin D is a very common occurrence in patients with DT1. Further long-term studies on children are required to determine the role of vitamin D on DT1.

The elderly population with diabetes is diverse with the majority experiencing a decline in physical and mental capabilities, impacting the entire diabetes management process. Therefore, a need for geriatric-specific guidelines, especially for the Asian population, was identified and subsequently developed by an expert panel across government and private institutions from several Asian countries. The panel considered clinical evidence (landmark trials, position papers, expert opinions), recommendations from several important societies along with their decades of clinical experience and expertise, while meticulously devising thorough geriatric-specific tailored management strategies. The creation of the ABCDE best practices document underscores and explores the gaps and challenges and determines optimal methods for diabetes management of the elderly population in the Asian region.

OBJECTIVE: Our objective was to assess the pattern of urine infections, the most common pathogen, and their susceptibility pattern to antibiotics among Saudi diabetic patients. METHODS: We performed a year-long cross-sectional study from January 2018 to January 2019 at KAAU Hospital in Riyadh, KSA. We cultured the urine specimens obtained from diabetic patients based on optimal aerobic and anaerobic microbiological methods. By adopting standard microbiological methods, we identified the bacterial isolates. We also followed the guidelines of the Clinical and Laboratory Standards Institute (CLSI) to do antibiotic susceptibility testing. RESULTS: A total of 100 isolates were evaluated, and a total of 22 organisms were isolated. The majority were multidrug-resistant organisms. Streptococcus haemolyticus was the most frequent organism and rated (15%). It was followed by Staphylococcus hominis (11%), Pseudomonas aeruginosa (9%), Enterococcus faecalis (9%), Enterococcus fiseum (7%), Escherichia coli (7%), Staphylococcus aureus (7%), Staphylococcus lantus (5%) and Klebsiella pneumoniae (5%). We also found multi-microbial infections. Most of the organisms were susceptible to tigecycline, gentamycin, and nitrofurantoin, rating (88%), (84%) and (78%), respectively. CONCLUSIONS: Our study revealed that a wide range of pathogens affects the diabetes patients. Staphylococcus haemolyticus is the most prevalent pathogen. We observed considerable antimicrobial resistance. Tigecycline had a wide sensitivity spectrum and was effective against most of the bacteria. Thus, it can be used as an empirical antibiotic.

OBJECTIVES: Aronia melanocarpa (Aronia) is a shrub with small berries, chokeberries. Chokeberries are claimed to possess health benefits due to a high content of polyphenols. Aronia is known to be extremely antioxidant; however, evidence for its health benefits is not established. This review gives an overview of the impact of Aronia on cardiometabolic risk factors and diseases. METHODS: Seventeen studies on cardiometabolic risk factors and diseases were identified through a systematic search on PubMed, Embase, and Cochrane. Inclusion criteria were studies with Aronia as intervention, performed in individuals with cardiometabolic disease or risk factors, e. g., type 2 diabetes (T2D), cardiovascular disease, hypertension, dyslipidaemia, impaired glucose tolerance, overweight, central obesity and smoking. Four of these studies were applicable for a quantitative analysis. RESULTS: Aronia did not influence body weight, circulating triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, or blood pressure. The quantitative analysis revealed a mean reduction in blood glucose of 0.44 mmol/l (P=0.0001) in the treatment group compared with the control group suggesting that Aronia treatment may have a beneficial impact on blood glucose. In addition, treatment durations of 6 weeks to 3 months tended to decrease low-density lipoprotein (LDL) cholesterol, while shorter treatment durations had no effect on LDL cholesterol. The quantitative analysis did not provide data on long-term effects of Aronia on lipids. CONCLUSIONS: More long-term high-quality randomized controlled studies are needed to clarify if dietary supplementation with Aronia has beneficial effects on cardiometabolic diseases.

1,5-anhydroglucitol (1,5-AG) is a biomarker of acute hyperglycemia in diabetology and also in cardiodiabetology. It is used to monitor fluctuating glucose levels. 1,5-AG is a monosaccharide that is biochemically similar to D-glucose and originates from the nutrition. The presence of 1,5-AG in blood and tissue is nearly constant due to reabsorption in the renal proximal tubule. In acute hyperglycemia, renal reabsorption is inhibited by glucose and 1,5- AG is excreted in the urine, while its serum level decreases rapidly. 1,5-AG reflects glucose excursions over 1-3 days to 2 weeks. In this regard, low levels of serum 1,5-AG can be a clinical marker of short- term glycemic derangements such as postprandial hyperglycemia, which is an important risk factor for the pathogenesis of coronary artery disease (CAD) as low levels of 1,5-AG reflect severe plaque calcification in CAD and correlate with high-density lipoprotein cholesterol (HDL-C) levels. For these reasons, 1,5-AG may also be a marker for atherosclerosis; in fact an even better marker than HbA1c or fructosamine which are normally used. 1,5-AG may also be a predictor of cardiovascular disease, left ventricular dysfunction after acute coronary syndrome (ACS), and mortality after ACS. This articles reviews the current knowledge on 1,5-AG related to its use as predictor for cardiovascular events.